Moving from Palliation to Cure: Progress in the Treatment of Non-Small Cell Lung Cancer

featuring

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine; Deputy Director, Yale Cancer Center
Assistant Dean for Translational Research, Yale School of Medicine

55 Park Street Auditorium | Zoom Access
Continental breakfast will be available

Needs: The treatment of NSCLC has rapidly evolved, especially with the recent discovery that Tagrisso (osimertinib) given after surgery dramatically increases the odds of survival for patients.

Objectives: Discuss new innovations in the care of NSCLC and potential advances in the pipeline, with a focus on the Center for Thoracic Cancers experience.

Dr. Herbst is internationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy for non-small cell lung cancer, specifically the process of linking genetic abnormalities of cancer cells to novel therapies.

Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs. He has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials to test these agents in advanced stage lung cancers.